Drugs /

rebastinib tosylate

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
rebastinib tosylate

Clinical Trials

View Clinical Trials for rebastinib tosylate

Rebastinib tosylate has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating rebastinib tosylate, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for rebastinib tosylate clinical trials.

Breast carcinoma, malignant solid tumor, and ovarian carcinoma are the most common diseases being investigated in rebastinib tosylate clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rebastinib Tosylate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rebastinib tosylate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dp-1919.to, dcc-2036
Drug Categories [2]:
ABL inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
ABL1, FLT3, KDR, TEK

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.